OV-329 is under clinical development by Ovid Therapeutics and currently in Phase I for Infantile Spasm (West Syndrome). According to GlobalData, Phase I drugs for Infantile Spasm (West Syndrome) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OV-329’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small molecule is under development for the treatment of resistant orphan epilepsy associated with tuberous sclerosis complex, focal seizures (partial seizure), infantile spasms and drug addiction. The drug candidate is administered through oral route. It acts by targeting GABA aminotransferase.
Ovid Therapeutics overview
Ovid Therapeutics is biopharmaceutical company that focused on the drug discovery and development for epilepsies and rare CNS disorders. The company product pipeline includes OV329 for the treatment of treatment of seizures, OV350 for the treatment of treating epilepsies. It also provides OV882, OV815, OV825 and Soticlestat. Ovid Therapeutics carries out the drug discovery and development. The company works in partnership with patients, clinicians and scientists, foundations, academic centers, regulatory agencies, and companies. It collaborates with Lundbeck and Angelman Syndrome foundations. Ovid Therapeutics is headquartered in New York, the US.
For a complete picture of OV-329’s drug-specific PTSR and LoA scores, buy the report here.